Case report highlights the feasibility of ASCT with CD19 CAR-T for sCNSL in COVID-19 patients, suggesting potential treatment pathways.
This paper reported a 64-year-old, secondary central nervous system lymphoma (sCNSL) patient with COVID-19 infection during CD19 chimeric antigen receptor T-cell (CAR-T) therapy following autologous stem cell transplantation (ASCT). Our findings demonstrate that the combination of ASCT and CAR-T for sCNSL may be feasible, even for SARS-CoV-2-positive immunocompromised lymphoma patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: